Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Liabilities: 2015-2025

Historic Total Liabilities for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to $408.5 million.

  • Cartesian Therapeutics' Total Liabilities fell 10.13% to $408.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $408.5 million, marking a year-over-year decrease of 10.13%. This contributed to the annual value of $441.8 million for FY2024, which is 0.64% down from last year.
  • As of Q3 2025, Cartesian Therapeutics' Total Liabilities stood at $408.5 million, which was up 4.37% from $391.4 million recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Total Liabilities high stood at $454.6 million for Q3 2024, and its period low was $45.7 million during Q3 2023.
  • For the 3-year period, Cartesian Therapeutics' Total Liabilities averaged around $333.1 million, with its median value being $430.9 million (2025).
  • As far as peak fluctuations go, Cartesian Therapeutics' Total Liabilities plummeted by 54.19% in 2022, and later surged by 894.56% in 2024.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Total Liabilities stood at $137.4 million in 2021, then tumbled by 47.54% to $72.1 million in 2022, then spiked by 517.11% to $444.7 million in 2023, then fell by 0.64% to $441.8 million in 2024, then dropped by 10.13% to $408.5 million in 2025.
  • Its Total Liabilities was $408.5 million in Q3 2025, compared to $391.4 million in Q2 2025 and $430.9 million in Q1 2025.